Loading…
ATRC
AtriCure, Inc.
NASDAQ· Healthcare· Medical Instruments & Supplies· CUSIP 04963C209
$59.30+2.83%Price as of Oct 23, 00:48 UTC · updated once a day, after the close
At a glance
AtriCure, Inc. (ATRC) is listed on NASDAQ and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Mason, United States and has 1,350 employees. The company is worth $3.02B and trades at 282.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $534.53M in fiscal 2025, up 14.9% from the year before. It reported a net loss of $11.45M. The share price is 3.9% below its 52-week high of $61.70. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $16.91M. In that quarter, 4 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $271.14K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $3.02B
- P/E
- 282.4x
- Forward P/E
- 136.6x
- P/B
- 5.8x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $0.21
- ROE
- 2.15%
- Profit margin
- 1.85%
- Revenue growth
- +12.80%
- Beta
- 1.25
- 52-week high
- $61.70
- 52-week low
- $25.36
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Steve CohenNew positionPoint72 Asset Management · Q2 2026$16.91M604.38K shares · 0.0% of portfolio
- Cliff AsnessAddedAQR Capital Management · Q2 2026$15.22M544.12K shares · 0.0% of portfolio
- Two SigmaReducedTwo Sigma Investments · Q2 2026$14.71M525.8K shares · 0.0% of portfolio
- Renaissance TechnologiesReducedRenaissance Technologies · Q2 2026$6.55M234.1K shares · 0.0% of portfolio
Ken GriffinAddedCitadel Advisors · Q2 2026$4.96M177.34K shares · 0.0% of portfolio
Ray DalioAddedBridgewater Associates · Q2 2026$2.14M76.31K shares · 0.0% of portfolio
Price over time
▼ -11.6% over 5Y.
today you would have $747.00▼ -25.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $39.56 | $30.56 | $35.69 | $44.38 | $69.53 | $55.67 | $32.51 | $30.60 | $18.24 | $19.57 | $22.44 | $19.96 | $18.68 | $6.90 | $11.10 | $10.27 | $6.04 | |
| P/E | — | — | — | — | — | 63.8x | — | — | — | — | — | — | — | — | — | — | — | — |
| P/S | 4.7x | 3.7x | 3.2x | 4.3x | 6.3x | 11.7x | 12.3x | 5.6x | 5.9x | 3.6x | 4.2x | 5.6x | 5.1x | 6.2x | 2.1x | 2.8x | 2.7x | — |
| P/B | 4.6x | 4.0x | 3.2x | 3.6x | 4.5x | 6.6x | 6.2x | 5.3x | 4.7x | 3.9x | 3.9x | 3.9x | 4.2x | 7.0x | 11.5x | 11.7x | 9.6x | — |
| EPS | -$0.24 | -$0.95 | -$0.66 | -$1.02 | $1.09 | -$1.14 | -$0.94 | -$0.62 | -$0.83 | -$1.05 | -$0.97 | -$0.61 | -$0.56 | -$0.47 | -$0.35 | -$0.25 | -$1.13 | |
| Profit margin | -14.00% | -2.14% | -9.61% | -7.62% | -14.06% | 18.30% | -23.32% | -15.25% | -10.48% | -15.39% | -21.49% | -20.97% | -15.09% | -14.00% | -10.73% | -8.47% | -6.43% | -30.25% |
| ROE | -14.23% | -2.33% | -9.70% | -6.53% | -10.17% | 10.38% | -11.68% | -14.23% | -8.48% | -16.69% | -19.79% | -14.58% | -12.23% | -15.79% | -60.27% | -34.94% | -22.66% | -96.52% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$6.93
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$18.01
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $6.93+Cash flow $18.01÷ 2 =$12.47
$12.47
2 methods answered, across 2 families.
$9.35
Room for errors in the reported numbers.
$59.30
-79.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DNLIDenali Therapeutics Inc. | $18.66 | — | 3.6x | 0.00% | -54.93% | $2.98B |
| ACHCAcadia Healthcare Company, Inc. | $31.88 | — | 1.5x | 0.00% | -41.45% | $2.97B |
| ELVNEnliven Therapeutics, Inc. | $41.93 | — | 3.4x | 0.00% | -15.31% | $3.07B |
| DYNDyne Therapeutics, Inc. | $15.77 | — | 3.7x | 0.00% | -81.56% | $2.94B |
| PRVAPrivia Health Group, Inc. | $22.89 | 109.0x | 3.7x | 0.00% | 4.31% | $2.92B |
| IRONDisc Medicine, Inc. | $75.03 | — | 4.5x | 0.00% | -39.08% | $2.88B |
About the company
- 1,350
- Mason, United States